SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-20-000668
Filing Date
2020-03-30
Accepted
2020-03-30 15:36:14
Documents
109
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F nymx_20f.htm 20-F 991223
2 EX-12 (A) nymx_12a.htm EX-12.A 8625
3 EX-12 (B) nymx_12b.htm EX-12.B 8143
4 EX-13 (A) nymx_13a.htm EX-13.A 2476
5 EX-13 (B) nymx_13b.htm EX-13.B 2442
  Complete submission text file 0001640334-20-000668.txt   5380928

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nymx-20191231.xml EX-101.INS 1181198
7 XBRL TAXONOMY EXTENSION SCHEMA nymx-20191231.xsd EX-101.SCH 103170
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20191231_cal.xml EX-101.CAL 51909
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20191231_def.xml EX-101.DEF 178849
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20191231_lab.xml EX-101.LAB 357302
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20191231_pre.xml EX-101.PRE 304010
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 20756690
SIC: 2835 In Vitro & In Vivo Diagnostic Substances